Who
Neil Josephson
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Iambic Therapeutics; Chief Medical Officer, Zymeworks; Chief Medical Officer, Zymeworks BC.
In numbers
- Trades disclosed
- 22
- Buys
- 1
- Sells
- 3
- Bought
- $71K
- Sold
- $60K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 6 Jul 2021
- Last trade
- 14 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Oct 2026filed 16 Oct 2026 | IAM Iambic Therapeutics | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 14 Oct 2026filed 16 Oct 2026 | IAM Iambic Therapeuticsoption or derivative | SEC FORM 4 Code A | —185,900 at $0.00 | filing |
| 10 Nov 2022filed 23 Dec 2022 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,885 at $0.00 | filing |
| 10 Nov 2022filed 23 Dec 2022 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code M | —5,885 at $0.00 | filing |
| 10 Nov 2022filed 23 Dec 2022 | ZYME ZymeworksBiotechnology | SEC FORM 4 Sold | $20K2,475 at $8.10 | filing |
| 10 Nov 2022filed 14 Nov 2022 | Zymeworks BCoption or derivative | SEC FORM 4 Code M | —5,885 at $0.00 | filing |
| 10 Nov 2022filed 14 Nov 2022 | Zymeworks BC | SEC FORM 4 Code M | —5,885 at $0.00 | filing |
| 10 Nov 2022filed 14 Nov 2022 | Zymeworks BC | SEC FORM 4 Sold | $20K2,475 at $8.10 | filing |
| 10 Nov 2022filed 14 Nov 2022 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,885 at $0.00 | filing |
| 10 Nov 2022filed 14 Nov 2022 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code M | —5,885 at $0.00 | filing |
| 10 Nov 2022filed 14 Nov 2022 | ZYME ZymeworksBiotechnology | SEC FORM 4 Sold | $20K2,475 at $8.10 | filing |
| 5 Jul 2022filed 5 Jul 2022 | Zymeworks | SEC FORM 4 Code A | $6,8781,525 at $4.51 | filing |
| 10 Mar 2022filed 11 Mar 2022 | Zymeworksoption or derivative | SEC FORM 4 Code M | —729 at $0.00 | filing |
| 10 Mar 2022filed 11 Mar 2022 | Zymeworksoption or derivative | SEC FORM 4 Code M | —1,666 at $0.00 | filing |
| 10 Mar 2022filed 11 Mar 2022 | Zymeworks | SEC FORM 4 Code M | —729 at $0.00 | filing |
| 10 Mar 2022filed 11 Mar 2022 | Zymeworks | SEC FORM 4 Code M | —1,666 at $0.00 | filing |
| 7 Jan 2022filed 11 Jan 2022 | Zymeworks | SEC FORM 4 Bought | $20K1,400 at $14.27 | filing |
| 7 Jan 2022filed 11 Jan 2022 | Zymeworks | SEC FORM 4 Bought | $51K3,600 at $14.28 | filing |
| 7 Jan 2022filed 7 Jan 2022 | Zymeworks | SEC FORM 4 Code A | $90665 at $13.94 | filing |
| 10 Nov 2021filed 12 Nov 2021 | Zymeworksoption or derivative | SEC FORM 4 Code A | —105,943 at $0.00 | filing |
News
Zymeworks Names Suzanne Monahan to Lead YUPELRI Commercial StrategyZYME · econotimes.com · 19 Oct 2026Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance BiopharmaZYME · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Neil Josephson; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.